
Evolus EOLS
$ 4.62
-1.39%
Annual report 2025
added 03-03-2026
Evolus EV - Enterprise Value 2011-2026 | EOLS
Annual EV - Enterprise Value Evolus
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 467 M | 1.03 B | 985 M | 601 M | 399 M | 408 M | 335 M | 375 M | 228 M | 84.6 M | 69.3 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.03 B | 69.3 M | 453 M |
EV - Enterprise Value of other stocks in the Drug manufacturers industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
6.79 M | - | 7.5 % | $ 6.35 M | ||
|
Alimera Sciences
ALIM
|
197 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
737 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
25.3 M | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
28.5 M | - | 0.86 % | $ 117 M | ||
|
Aurora Cannabis
ACB
|
106 M | $ 3.28 | -0.91 % | $ 86.3 M | ||
|
China Pharma Holdings
CPHI
|
11.1 M | $ 0.63 | - | $ 11 M | ||
|
Catalent
CTLT
|
16.7 B | - | - | $ 11.5 B | ||
|
Athenex
ATNX
|
209 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
756 M | - | - | $ 2.06 B | ||
|
Cronos Group
CRON
|
3.84 B | $ 2.54 | 0.79 % | $ 1.33 B | ||
|
DURECT Corporation
DRRX
|
3.37 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
1.2 B | $ 8.03 | -0.25 % | $ 411 M | ||
|
Endo International plc
ENDP
|
-710 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
7.15 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
10.2 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
284 M | - | 2.45 % | $ 38.1 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
124 M | $ 3.17 | 3.77 % | $ 44.6 M | ||
|
Bausch Health Companies
BHC
|
29.9 B | $ 4.97 | -2.74 % | $ 1.81 B | ||
|
Pacira BioSciences
PCRX
|
1.68 B | $ 22.73 | 0.35 % | $ 1.05 B | ||
|
Harrow Health
HROW
|
2.21 B | $ 35.35 | 3.96 % | $ 1.3 B | ||
|
OptiNose
OPTN
|
312 M | - | - | $ 1.08 B | ||
|
Rockwell Medical
RMTI
|
57.3 M | $ 1.05 | 2.94 % | $ 24.5 M | ||
|
Solid Biosciences
SLDB
|
616 M | $ 6.79 | -4.97 % | $ 594 M | ||
|
Eagle Pharmaceuticals
EGRX
|
457 M | - | -39.89 % | $ 27.7 M | ||
|
Sundial Growers
SNDL
|
-17.5 M | $ 1.36 | - | $ 3.37 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
7.57 M | $ 2.34 | -8.24 % | $ 2.9 M | ||
|
Relmada Therapeutics
RLMD
|
251 M | $ 6.08 | 3.67 % | $ 240 M | ||
|
OrganiGram Holdings
OGI
|
456 M | $ 1.37 | 0.37 % | $ 402 M | ||
|
Tilray
TLRY
|
1.96 B | $ 6.43 | -0.31 % | $ 3.97 B | ||
|
PetIQ
PETQ
|
280 M | - | 1.64 % | $ 400 M | ||
|
PLx Pharma
PLXP
|
73.8 M | - | -27.8 % | $ 2.56 M | ||
|
ProPhase Labs
PRPH
|
145 M | - | - | $ 5.07 M | ||
|
Veru
VERU
|
111 M | $ 2.3 | - | $ 310 M | ||
|
Jupiter Wellness
JUPW
|
91.9 M | - | - | $ 33.6 M | ||
|
Viatris
VTRS
|
41.3 B | $ 13.44 | 1.09 % | $ 16.1 B | ||
|
Radius Health
RDUS
|
700 M | - | - | $ 1.42 B | ||
|
Lannett Company
LCI
|
648 M | - | 1.15 % | $ 7.11 M | ||
|
SCYNEXIS
SCYX
|
26.3 M | $ 0.87 | -0.59 % | $ 43.4 M | ||
|
TherapeuticsMD
TXMD
|
33.6 M | $ 2.29 | -1.07 % | $ 23.9 M | ||
|
cbdMD
YCBD
|
7.85 M | $ 0.77 | 1.21 % | $ 3.32 M | ||
|
Organogenesis Holdings
ORGO
|
392 M | $ 2.4 | -2.83 % | $ 316 M | ||
|
Neoleukin Therapeutics
NLTX
|
-110 M | - | - | $ 193 M | ||
|
Perrigo Company plc
PRGO
|
7.03 B | $ 9.74 | 1.78 % | $ 1.35 B | ||
|
Canopy Growth Corporation
CGC
|
459 M | $ 0.95 | -1.5 % | $ 102 M | ||
|
Assertio Holdings
ASRT
|
238 M | $ 16.05 | 14.64 % | $ 103 M | ||
|
Recro Pharma
REPH
|
220 M | - | -4.76 % | $ 65.3 M | ||
|
Tricida
TCDA
|
506 M | - | - | $ 3.25 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-22.6 M | - | - | $ 55.5 M |